Intech Investment Management LLC Acquires 16,785 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

Intech Investment Management LLC grew its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 164.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,985 shares of the medical equipment provider's stock after acquiring an additional 16,785 shares during the period. Intech Investment Management LLC owned about 0.06% of BioLife Solutions worth $701,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in the business. Steward Partners Investment Advisory LLC bought a new stake in BioLife Solutions during the 4th quarter valued at approximately $26,000. Mark Sheptoff Financial Planning LLC purchased a new stake in BioLife Solutions during the 3rd quarter valued at approximately $28,000. Quest Partners LLC bought a new stake in shares of BioLife Solutions during the third quarter valued at approximately $57,000. Smartleaf Asset Management LLC lifted its holdings in shares of BioLife Solutions by 27.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider's stock worth $117,000 after buying an additional 950 shares in the last quarter. Finally, Stifel Financial Corp boosted its position in shares of BioLife Solutions by 5.4% during the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider's stock worth $325,000 after acquiring an additional 670 shares during the last quarter. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on BLFS. KeyCorp lifted their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an "overweight" rating in a report on Friday, December 13th. Northland Securities boosted their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 8th. Benchmark reissued a "buy" rating and set a $30.00 price target on shares of BioLife Solutions in a research note on Thursday, December 19th. HC Wainwright lifted their price objective on BioLife Solutions from $27.00 to $30.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Finally, StockNews.com upgraded BioLife Solutions from a "sell" rating to a "hold" rating in a research report on Wednesday, March 19th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $29.86.

Remove Ads

Insider Buying and Selling at BioLife Solutions

In other BioLife Solutions news, insider Sarah Aebersold sold 5,632 shares of the stock in a transaction on Friday, March 14th. The stock was sold at an average price of $24.96, for a total value of $140,574.72. Following the sale, the insider now owns 45,860 shares in the company, valued at $1,144,665.60. This trade represents a 10.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Aby J. Mathew sold 1,597 shares of the business's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total transaction of $39,925.00. Following the sale, the executive vice president now directly owns 260,601 shares of the company's stock, valued at $6,515,025. This represents a 0.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 21,117 shares of company stock worth $534,442 over the last 90 days. Company insiders own 2.20% of the company's stock.

BioLife Solutions Trading Up 2.6 %

NASDAQ:BLFS traded up $0.67 during midday trading on Thursday, hitting $26.17. 279,416 shares of the company traded hands, compared to its average volume of 348,880. The firm has a market capitalization of $1.23 billion, a P/E ratio of -24.69 and a beta of 2.04. The firm's fifty day moving average is $26.35 and its 200-day moving average is $25.52. BioLife Solutions, Inc. has a 12-month low of $14.84 and a 12-month high of $29.55. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last announced its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.32. The business had revenue of $22.71 million for the quarter, compared to the consensus estimate of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same quarter in the prior year, the firm posted ($0.21) earnings per share. On average, sell-side analysts predict that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.